Identification of a bladder cancer-specific ligand using a combinatorial chemistry approach
Hongyong Zhang(Union Hospital), Chong-xian Pan(VA Northern California Health Care System), Primo N. Lara(UC Davis Comprehensive Cancer Center), Christopher P. Evans(University of Nevada, Reno), Xiaobing Wang(Shanghai Changzheng Hospital), Paul T. Henderson(Quantum Leap Healthcare Collaborative), James A. Bassuk(Seattle Children's Hospital), Olulanu H. Aina(University of California, Davis), Ralph de Vere White(University of California, Davis), Kit S. Lam(University of California System)
Cited by 53
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Combination strategies to maximize the benefits of cancer immunotherapy
|Journal of Hematology & Oncology|2021|651
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study
|European Urology|2016|414
Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2011|320
Stimuli-responsive cross-linked micelles for on-demand drug delivery against cancers
|Advanced Drug Delivery Reviews|2013|295